Latest Japanese recommendations include first nod for Novo's insulin degludec
This article was originally published in Scrip
Executive Summary
Novo Nordisk's Tresiba (insulin degludec) has received its first positive approval opinion worldwide, in Japan, following a regulatory filing in this market last December.